April 2023 Br J Cardiol 2023;30:45–50
Sarah Birkhoelzer
Preparing for the next 25 years Opening the meeting, BSH Chair Professor Roy Gardner (University of Glasgow) spoke about the BSH‘s aim to reduce HF mortality by 25% in 25 years, which would need the bringing together of all stakeholders to improve: Prevention strategies Identifying those at risk Early accurate diagnosis Appropriate treatment In his speech, he encouraged us to be more ambitious for further progress, to raise awareness of HF, and to educate more widely to achieve further progress and benefit more patients. 25 Fellows for 25 years Table 1. The new British Society for Heart Failure Fellows John Baxter, Sunderland Lynd
February 2023 Br J Cardiol 2023;30:12–15
Karin Pola, Sarah Birkhoelzer
What’s new in transplantation Are kidney donors worse off? The meeting was opened by Dr Anna Price (Queen Elizabeth University Hospital, Birmingham) who addressed the long-term cardiovascular effects of unilateral nephrectomy in living kidney donors.1 Previous studies have shown a significant prevalence of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD),2,3 but the effects of reduced renal function in living kidney donors has been unexplored until now. A recent study by Price et al. demonstrated that living kidney donors had a reduction in estimated glomerular filtration rate (eGFR) from 95 to 67 ml/min
March 2018 doi:10.5837/bjc.2018.007
Emma Johns, Gerry McKay, Miles Fisher
(more…)
September 2014 Br J Cardiol 2014;21:99
BJCardio Staff
BSH Parliament day Professor Andrew Clark (President of the British Society for Heart Failure) is pictured here (centre) carrying out an echocardiogram in the House of Commons. He was at a BSH event to help raise awareness that a person diagnosed with heart failure is likely to have a worse prognosis than if they were diagnosed with most cancers. This is despite the availability of specialist heart failure services that can have a remarkable impact on a patient’s chance of survival, but for which there is inconsistent access over the UK leading to wide variations in care and outcomes. Over 60 MPs, Peers, and professional and patient groups
November 2012 Br J Cardiol 2012;19:158–9
BJCardio Staff
While general recommendations regarding the intensiveness of glycaemic therapy focused in the past on a HbA1c target below 7%, the new statement emphasises that goals must be individualised, with the precise target taking into account patient’s attitude and expected treatment efforts, the risk associated with glycaemia and other adverse effects, disease duration, life expectancy, other co-morbidities, established vascular complications, and the patient’s own resources and support system. It notes, for example, some patients may feel that the weight gain associated with a particular diabetes therapy is unacceptable, whereas others may cons
September 2010 Br J Cardiol 2010;17:231–4
James G Boyle, Gerard A McKay, Miles Fisher
(more…)
March 2004 Br J Cardiol 2004;11:138-43
ohn HB Scarpello
No content available
March 2003 Br J Cardiol 2003;10:128-36
Clifford J Bailey, Caroline Day
No content available
February 2002 Br J Cardiol 2002;9:115-19
Clifford J Bailey, Ian W Campbell
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits